Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIL Therapy in Metastatic Melanoma
NCT03526185Phase 1Terminated
- Sponsor
- Yale University
- Start
- Feb 2018
- Primary completion
- Dec 2020
- Modality
- Monoclonal Antibodies, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of autologous tumor-infiltrating lymphocytes in melanoma (2 arms), sponsored by Yale University. Primary endpoints: Adverse Events up to 12 months and Serious Adverse Events up to 12 months. Started Feb 2018; status: terminated.
02
Drugs
autologous tumor-infiltrating lymphocytes
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03526185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03526185.